Certolizumab in Recurrent Implantation Failure (RIF)

NCT05930613 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

161

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Unexplained Implantation Failure

Interventions

DRUG: Certolizumab (CIMZIA® ; TNF-α antagonist)
DRUG: Placebo (NaCl 0.9 % solution)

Sponsor

Assistance Publique - Hôpitaux de Paris